The Conversation (0)
Nascent Biotech (OTC:NBIO), a clinical-stage biotech company which works to develop monoclonal antibodies for cancer treatment, raised $2.1 million to develop their lead product, Pritumumab.
Nascent Biotech (OTC:NBIO), a clinical-stage biotech company which works to develop monoclonal antibodies for cancer treatment, raised $2.1 million to develop their lead product, Pritumumab.
According to a press release:
Pritumumab is a fully human monoclonal antibody being developed initially for the treatment of malignant and non malignant Gliomas.
One of the biggest challenges in the development of any antibody product is to show that it can be manufactured, at appropriate scale, to clinical grade and in sufficient quantity for human trials. We have attained this goal and manufactured more than enough product to complete our initial Phase 1/Phase 2 human trials on Brain Cancers, with more than adequate amounts left over to initiate trials in other epithelial cancers such as breast, lung, colon and pancreas. Pritumumab is unique in its ability to react strongly with all these major malignancies.
An additional challenge is to understand the toxicity profile. We have completed a toxicology study, in compliance with FDA guidance, and we have demonstrated no in life toxicities in the two species studied (Monkey and Rat).
Another significant milestone worth noting is that the FDA granted Nascent Biotech an Orphan Drug Designation for Gliomas (brain cancer).
Click here to read the full press release from Nascent Biotech.